All articles tagged with #long acting injectable
Scientists from the University of South Australia have developed a biodegradable, long-acting injectable gel that delivers levodopa and carbidopa steadily over a week, potentially transforming Parkinson's treatment by reducing dosing frequency and improving patient compliance. The formulation has shown promising safety and effectiveness in lab tests, with plans for clinical trials and commercialization.
A new FDA-approved long-acting injectable drug called Yestugo offers up to six months of HIV protection, providing an alternative to daily pills but not preventing other STIs. Experts emphasize that it should complement, not replace, comprehensive sexual health practices like condom use, especially as STI rates, such as genital discharge syndromes, continue to rise in Jamaica. The medication is expected to improve adherence for those struggling with daily regimens, but awareness of its limitations remains crucial.
The rollout of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV without delay can have a significant impact on the HIV epidemic, particularly in settings with high HIV incidence. A study showed that CAB-LA was superior to the daily oral regimen in preventing HIV infection. By expanding PrEP coverage with CAB-LA, the projected HIV incidence decreased in simulation models for Atlanta, Montreal, and the Netherlands. Increasing PrEP coverage by 11 percentage points by 2032 could lead to a reduction of over 45% in new HIV acquisitions. Offering CAB-LA to current and prospective PrEP patients could improve adherence and increase the effectiveness of HIV prevention.